- Home
- MDAI vs CNTX Comparison
MDAI vs CNTX Comparison
Compare MDAI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | CNTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 57.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDAI | CNTX |
|---|---|---|
| Price | $1.75 | $0.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $6.60 |
| AVG Volume (30 Days) | 160.6K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $0.49 |
| 52 Week High | $2.97 | $3.62 |
Technical Indicators
Market Signals| Indicator | MDAI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 32.19 |
| Support Level | $1.62 | N/A |
| Resistance Level | $1.77 | $0.68 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 80.00 | 8.78 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.